John Libbey Eurotext

Quinidine therapy and therapeutic drug monitoring in four patients with KCNT1 mutations Volume 21, numéro 1, February 2019

Illustrations

  • Figure 1
  • Figure 2
Auteurs
1 National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
2 Seirei Hamamatsu General Hospital, Department of Child Neurology, Hamamatsu
3 Yokohama City University Graduate School of Medicine, Department of Human Genetics, Yokohama
4 Hamamatsu University School of Medicine, Department of Biochemistry, Hamamatsu,
5 Shizuoka Children's Hospital, Department of Cardiology, Shizuoka
6 Department of Pediatrics School of Medicine, Fukuoka University, Fukuoka, Japan
* Correspondence: Shinsaku Yoshitomi National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorder, 886 Urushiyama, Aoi-ku, Shizuoka 420-8688, Japan

Aims

Several recent studies have reported potassium sodium-activated channel subfamily T member 1 (KCNT1) mutations in epilepsy patients on quinidine therapy. The efficacy and safety of quinidine for epilepsy treatment, however, remains controversial.